Targeting DNA Repair in Cancer: Beyond PARP Inhibitors

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Germline mutations in DNA repair/damage-response (DDR) genes predispose individuals to cancer.
• Tumors often acquire somatic mutations that impair DDR and DNA repair mechanisms.
• Synthetic lethality offers a therapeutic window for DDR-deficient cancers, as seen with PARP inhibitors for BRCA1/2-mutated ovarian cancers.

Purpose of the Study:

• To explore novel therapeutic strategies targeting DDR pathways in cancer.
• To discuss the complexities of cellular DDR processes.
• To address challenges in patient selection and combination therapy development for DDR inhibitors.

Main Methods:

• Review of cellular DDR mechanisms involving DNA damage sensing, signaling, and repair.
• Analysis of existing and emerging DDR inhibitors in preclinical and clinical development.
• Examination of lessons learned from successful PARP inhibitor registration.

Main Results:

• DDR pathways involve intricate protein networks for DNA damage sensing, cell-cycle control, apoptosis, and repair.
• Numerous DDR inhibitors targeting various components are under investigation.
• Understanding DDR pathway complexity is crucial for clinical success.

Conclusions:

• Targeting DDR pathways represents a promising therapeutic avenue for cancer treatment.
• Exploiting synthetic lethality is a validated strategy for DDR-deficient malignancies.
• Further research is needed to optimize patient selection and develop rational drug combinations for DDR inhibitors.